ReviewInfluenza and other respiratory viruses2013
Advances in the development of universal influenza vaccines.
Review in Influenza and other respiratory viruses, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Healthcare Settings and Infection Prevention: Today's Procedures in Light of the "Instructions for Disinfection" Issued During the 1817 Typhus Epidemic in the Grand Duchy of Tuscany (Pre-Unification Italy).Epidemiologia (Basel, Switzerland) · 2025Article
- Immunogenicity Measures of Influenza Vaccines: A Study of 1164 Registered Clinical Trials.Vaccines · 2020Article
- Peter's Paradigm and Pandemic Preparedness.Viral immunology · 2020Article
- OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes.NPJ vaccines · 2019Article
- Vaccination potential of B and T epitope-enriched NP and M2 against Influenza A viruses from different clades and hosts.PloS one · 2018Article
- Influenza virus surveillance in Argentina during the 2012 season: antigenic characterization, genetic analysis and antiviral susceptibility.Epidemiology and infection · 2016Article
- Characterisation of a wild-type influenza (A/H1N1) virus strain as an experimental challenge agent in humans.Virology journal · 2015Article
- In Silico Identification of Highly Conserved Epitopes of Influenza A H1N1, H2N2, H3N2, and H5N1 with Diagnostic and Vaccination Potential.BioMed research international · 2015Article
- Bringing influenza vaccines into the 21st century.Human vaccines & immunotherapeutics · 2014Article
- The Possible Impact of Vaccination for Seasonal Influenza on Emergence of Pandemic Influenza via Reassortment.PloS one · 2014Article
- Fast vaccine design and development based on correlates of protection (COPs).Human vaccines & immunotherapeutics · 2014Review
- Immunological assessment of influenza vaccines and immune correlates of protection.Expert review of vaccines · 2013Review
- Novel vaccine strategies against emerging viruses.Current opinion in virology · 2013Review
- Rise of the microbes.Virulence · 2013Review
- Influenza epidemiology in Italy two years after the 2009-2010 pandemic: need to improve vaccination coverage.Human vaccines & immunotherapeutics · 2013Article
- A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin.Nature structural & molecular biology · 2013Article
- Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1.Scientific reports · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the widespread availability and use of influenza vaccines, influenza still poses a considerable threat to public health. Vaccines against seasonal influenza do not offer protection against pandemic viruses, and vaccine efficacy against seasonal viruses is reduced in seasons when the vaccine composition is not a good match for the predominant circulating viruses. Vaccine efficacy is also reduced in older adults, who are one of the main target groups for vaccination. The continual threat of pandemic influenza, with the known potential for rapid spread around the world and high mortality rates, has prompted researchers to develop a number of novel approaches to providing immunity to this virus, focusing on target antigens which are highly conserved between different influenza A virus subtypes. Several of these have now been taken into clinical development, and this review discusses the progress that has been made, as well as considering the requirements for licensing these new vaccines and how they might be used in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.